Side-by-side · Research reference
DihexavsThymalin
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AAnimal-StrongHUMAN-REVIEWED7/28 cited
BHuman-MechanisticAUTO-DRAFTED12/40 cited
Dihexa
Angiotensin IV Analogue · Pre-Clinical
Not established — animal studies only
Thymalin
Immune restorer · Russian peptide bioregulator
IM · Daily for 5–10 days · 1-2×/year
01Mechanism of Action
Parameter
Dihexa
Thymalin
Primary target
c-Met receptor (HGF receptor tyrosine kinase)
T-cell precursors + thymus-axis maturation pathwayKhavinson 2002
Pathway
HGF/c-Met receptor activation → downstream signaling cascade → synaptogenesis and dendritic arborization
Modulation of T-cell differentiation + thymic hormone restoration in age-involuted thymusKhavinson 2002
Downstream effect
Induction of dendritic arborization, synapse formation, neurogenesis, and neuroprotection in rodent models
Restored T-cell populations, improved immune surveillance, reduced infection rates in elderlyKhavinson 2002
Feedback intact?
—
—
Origin
Small-molecule angiotensin IV analogue designed to activate HGF/c-Met systemWright 2015
Polypeptide fraction isolated from calf thymus extractKhavinson 2002
Antibody development
—
—
02Dosage Protocols
Parameter
Dihexa
Thymalin
Human dosing
Not established — no human trials
—
Animal studies
Mouse/rat models only — dosing not translatable to humans
—
Clinical status
No Phase 1, 2, or 3 trials published
—
Frequency
—
Once daily during cycle
Lower / starter dose
—
2.5 mg / day
Duration
—
5–10 day cycles, 1–2× per year
Reconstitution
—
Saline or bacteriostatic water
Timing
—
Morning preferred
Half-life
—
Hours (estimated)
04Side Effects & Safety
Parameter
Dihexa
Thymalin
Human safety data
None available — no human clinical trials
—
Theoretical c-Met risks
c-Met receptor activation has been implicated in tumorigenesis; unknown cancer risk profile
—
Pre-clinical tolerability
Not systematically reported in available studies
—
Injection site reaction
—
Mild erythema at IM site
Allergic reaction
—
Rare hypersensitivity to bovine-derived polypeptide
Autoimmune flare
—
Theoretical risk in active autoimmune disease
Long-term safety
—
Limited Western data
Pregnancy / OB
—
Avoid
Absolute Contraindications
Dihexa
- ·Not approved for human use — research compound only
Thymalin
- ·Pregnancy / breastfeeding
- ·Bovine protein hypersensitivity
Relative Contraindications
Dihexa
- ·Theoretical contraindication: active or history of malignancy (c-Met pathway involvement in cancer)
Thymalin
- ·Active autoimmune disease
- ·Concurrent immunosuppressant therapy
05Administration Protocol
Parameter
Dihexa
Thymalin
1. Human administration
No established protocol. Dihexa has not been tested in human subjects. Animal studies used various routes (typically subcutaneous or intraperitoneal in rodents) not translatable to clinical use.
Add 1–2 mL saline or bacteriostatic water per 10 mg vial.
2. Legal status
Pre-clinical research compound. Not approved by FDA or any regulatory authority for human use.
Intramuscular — deltoid or gluteal. Rotate sites.
3. Timing
—
Morning preferred during cycle.
4. Storage
—
Lyophilised: refrigerate, light-protected. Reconstituted: use immediately.
5. Needle
—
23–25G, 25–38 mm IM needle.
06Stack Synergy
Dihexa
— no documented stacks
Thymalin
+ Thymosin α-1
ModerateThymalin is a polypeptide complex; Thymosin α-1 is a single purified peptide. Both target the thymus-axis but at different levels — Thymalin restores broad thymic signaling; Tα-1 provides a specific molecular activator. Anecdotally combined for elderly immune support.
- Thymalin
- 5–10 mg IM · daily × 7 days
- Thymosin α-1
- 1.6 mg SQ · 2× weekly during the cycle
- Primary benefit
- Broad thymic restoration + targeted immune activation